We began to print laboratory data on prescriptions and introduced a system called the checking prescription assist system (the assist system) for a high-quality, effective system of checking prescriptions. The assist system prints drug information for each registered drug and we registered drugs affected by renal function. When a registered drug for a patient with a creatinine clearance of less than 60 mL/min is prescribed, an assist sheet on which information of recommended dosage for each renal function is printed. The purpose of this study is to evaluate a change of prescription questions and the utility of using prescriptions on which laboratory data is printed and the assist system. We investigated inquired prescriptions in three periods:

Hand-foot skin reaction (HFSR) caused by regorafenib deteriorates the quality of life (QOL) of patients. Risk factors of HFSR by regorafenib in the Japanese population have not been clarified. We conducted a retrospective survey to clarify the risk factors of HFSR by regorafenib in 45 patients with unresectable advanced or recurrent colorectal cancer. The initial dose of regorafenib was reduced in 19 (42.2％) patients. The median time to treatment failure (TTF) was 42 days, and median relative dose intensity (RDI) was 50％ over the entire treatment period. HFSR was developed in 31 patients (68.9％), and 22 of them (48.9％) were assessed as Grade 2 or higher. In the Cox proportional hazards regression analysis, significantly prolonged factors of TTF by regorafenib were a history of three or more chemotherapy regimens (hazard ratio 0.484, 95％ confidence interval: 0.247-0.948; P = 0.034) and HFSR assessed as Grade 2 or higher (hazard ratio 0.378, 95％ confidence interval: 0.163-0.620; P = 0.001). In the multivariable logistic regression analysis, significant risk factors of severe HFSR assessed as Grade 2 or higher were under 65 years old (

Treatment for chemotherapy-induced nausea and vomiting CINV has improved signi cantly with the development of antiemetic drugs. We conducted a prospective observational study to clarify the quality of life QOL impact of antiemetic therapy recommended by the Japanese Cancer Therapy Association JSCO guidelines for Japanese breast cancer patients receiving an anthracycline plus cyclophosphamide regimen ACR. This was an open, single-center, prospective observational study conducted in Yokohama City University Medical Center. Antiemetic therapy recommended by the JSCO guidelines was implemented for all cases treated therein i.e., aprepitant, dexamethasone, and palonosetron. The primary endpoint was no impact on daily living NIDL rate during a 120-hour period following chemotherapy i.e., overall phase. We use the Japanese version of the Functional Living Index-Emesis FLIE to evaluate the impact of CINV on QOL. There were 118 analyzable cases. The NIDL rate during the overall phase was 44.9 , and was signi cantly lower than the complete response CR rate of 58.5 i.e., no emetic responses and no rescue medication ; P 0.037. Age 55 years P 0.008 and a history of morning sickness P 0.005 were identi ed as independent risk factors of NIDL P 0.05. Among Japanese breast cancer patients receiving ACR and a combination of aprepitant, dexamethasone, and palonosetron, the NIDL rate was relatively low at approximately 45. A more effective antiemetic therapy should therefore be developed for patients QOL that takes NIDL risk factors into account. In addition, our results suggested that the CR rate is insuf cient for evaluating the effect of antiemetic therapy on a patient s QOL.

No abstract